variation
gallery

🔬 Research Use Only

TB-500 Research Peptide

Recovery Research

TB-500 is a synthetic thymosin beta-4 fragment used in laboratory peptide signaling studies focused on cell migration behavior, actin-associated pathway activity, and tissue-response modeling. As a TB-500 research peptide supplier, GMR Peptides positions this compound for controlled research use, peptide purity verification, and receptor pathway research peptide workflows. This synthetic peptide fragment is offered for experimental evaluation only and is not presented for therapeutic, diagnostic, or consumer use.

Select Dosage

Bundle & Save

1 bottle

1 bottle

2 bottle

4.99% OFF
2 bottle

3 bottle

7.5% OFF
3 bottle
Bundle & Save

1 bottle

$44.99

2 bottle

Save 4.99%

3 bottle

Save 7.5%
$44.99

20 in stock

. ships today if ordered before 3pm ET

per 10mg vial

SSL 256-bit

Secure Checkout

Free shipping

On orders over $200

60-day returns

Money-back guarantee

🚚 Get 2 day shipping when you spend $250 or More

🚚 Free shipping over $200

🔄 60-day money back

🔒 SSL Secure

📦 Discreet packaging

We Accept

variation
gallery

🔬 Research Use Only

TB-500 Research Peptide

Recovery Research

TB-500 is a synthetic thymosin beta-4 fragment used in laboratory peptide signaling studies focused on cell migration behavior, actin-associated pathway activity, and tissue-response modeling. As a TB-500 research peptide supplier, GMR Peptides positions this compound for controlled research use, peptide purity verification, and receptor pathway research peptide workflows. This synthetic peptide fragment is offered for experimental evaluation only and is not presented for therapeutic, diagnostic, or consumer use.

Select Dosage

Bundle & Save

1 bottle

1 bottle

2 bottle

4.99% OFF
2 bottle

3 bottle

7.5% OFF
3 bottle
$44.99

🚚 Get 2 day shipping when you spend $250 or More

🚚 Free shipping over $200

🔄 60-day money back

🔒 SSL Secure

📦 Discreet packaging

We Accept

99%+ Purity Guaranteed

Every batch verified by accredited US labs

Shipment Protection

Every order fully covered

60-Day Money Back

No questions asked

Certificate of Analysis and Peptide Purity Verification

🧪 Lab Verified

Third-party analytical review supports batch documentation for TB-500 receptor pathway research peptide evaluation, including identity confirmation, peptide purity verification, and laboratory reference use.

TB-500 - 10mg Vial

Lot #2026-03-001-N

PASS
0%

Verified Purity

Labeled 10mg
Actual 11.35 mg
Tested 03/24/2026
Method HPLC with UV Detection coupled with Mass Spectrometry (LCMS/MS)
Lab Freedom Diagnostics
Status In Stock
Download Certificate

Third-Party Independent Verification — All GMR Peptides products are tested by accredited external laboratories using HPLC and Mass Spectrometry. We never self-certify. Results are published on every product page with no exceptions.

61%

Faster Re-epithelialization

Relative epithelial closure observation in preclinical tissue model
No

Serious Adverse Events

Serious adverse event signal not observed in limited phase dataset
170+

Cited Studies

Published references and cited experimental literature
43

Amino Acids

Amino acid sequence length
0.95-1.9hrs

Half-Life

Observed plasma half-life range reported in experimental literature

Mechanism and Pathway Signaling Overview

ACTIN
RESEARCH METHODOLOGY

Actin-Associated Signaling

TB-500 is commonly discussed as a synthetic thymosin beta-4 fragment research peptide evaluated in laboratory settings for its interaction with actin-associated cellular processes, peptide signaling dynamics, and migration-related pathway behavior.

Actin Sequestration

G-Actin Binding

Cytoskeletal Organization Behavior

  • Observed in actin-associated pathway discussions
  • Linked to polymer sequestration modeling
  • Evaluated in movement-related signaling models
ILK Kinase

Receptor Interaction

Intracellular Signaling Modulation

  • Described through model-based pathway evaluation
  • Associated with signaling coordination behavior
  • Observed in controlled laboratory settings
Tβ4 Fragment

Peptide Dynamics

Synthetic Fragment Evaluation

  • References peptide signaling dynamics
  • Focused on pathway signaling behavior
  • Limited to controlled model observations
↗ Laboratory Reference — Model-Based Signaling Interpretation
MOTILITY

Cell Migration Observation

TB-500 has been explored in preclinical systems for peptide signaling dynamics associated with directional cell movement, epithelial response observation, and matrix-related signaling behavior.

Directional Movement Signaling Observed in models
Epithelial Response Observation Evaluated
Matrix-Related Signaling Tracked
Pathway Behavior Interpreted
Preclinical Systems: Language reflects signaling dynamics and experimental observation only.
NF-κB

Inflammation-Related Pathway Signaling

Experimental observations involve NF-κB-associated signaling, cytokine-related response markers, and pathway signaling behavior in controlled laboratory models. This analysis avoids therapeutic implications.

Laboratory Model Context: References are limited to signaling behavior, response-marker observation, and controlled pathway interpretation.
NF-κB Signaling Markers Observed
Cytokine-Related Pathways Referenced
Peptide Signaling Dynamics Evaluated
Controlled Model Analysis Maintained
✦ Laboratory Analysis

Observed Signaling Activity Summary

Experimental model findings and receptor pathway research peptide review

📋 Experimental Observation Overview
0 Serious Adverse Events
LIMIT PHASE DATASET | PRECLINICAL MODEL

Laboratory Peptide Signaling Studies

Relative epithelial response marker at Day 7 61%
Relative epithelial response marker at Day 4 42%
Keratinocyte movement observation 200%
Surface closure pattern observation 11%
🔬 Research-Use Limitations: This section summarizes published experimental observations involving TB-500. Progress indicators reflect reported model findings and laboratory outcome markers from preclinical settings.
↗ Published Literature — Experimental Model Reporting
📈 Key Metrics

Experimental Observation Summary

Evaluation of epithelial closure timing and dose-dependent signaling patterns as reported in established research-grade analytical studies.

3.75 mg/kg observed dose
Reported Model Finding Dose-context signaling review
14 days observation window
Investigational Reporting Laboratory study duration
100% Analytical Completion
Study Continuation Marker Investigational reporting note
⚠️ Disclaimer: Human clinical evidence remains limited; current interpretation is based primarily on preclinical data and investigational reporting.
🧪 Preclinical Evidence

Dose-Context Signaling Observations

Findings across investigational dose ranges are presented as laboratory observation markers rather than therapeutic claims.

2 mg/kg 29%
3.75 mg/kg (Peak Observation) 35%
💡 Dose-Context Review: Values are framed as investigational findings derived from model-based reporting.
↗ Investigational Reporting — Dose-Context Findings
📋 vs Saline Controls

Observed Signaling Patterns

Comparison summary of reported model findings and laboratory outcome markers relative to control benchmarks.

Relative epithelial response at Day 7 +61%
Keratinocyte movement observation +200%
↗ Model-Based Observation Summary

Laboratory Research Applications & Model Context

This TB-500 research peptide analysis positions the compound for scientific investigation into pathway signaling behavior, actin-related peptide activity, and experimental tissue-response modeling.

Migration
MODELS

Directional cell movement and cytoskeletal organization signaling behavior in laboratory models.

↗ Experimental Model Review
Cardio
OBSERVATION

Exploratory peptide signaling studies involving ILK activity and cardiovascular response patterns.

↗ Cardiovascular Context
Neuro
MODELS

Functional observation markers and experimental timing data in preclinical neurologic models.

↗ Investigative Literature
Ocular
EVALUATION

Ocular surface laboratory model evaluation and epithelial response observation in research.

↗ Ophthalmic Settings
💗 CARDIOVASCULAR

Cardiovascular Model Observation

Exploratory laboratory studies have referenced integrin-linked kinase (ILK) activity and cell motility markers in cardiovascular research models.

ILK Activity Observation Reported Marker
Cell Motility Signaling +90%
Experimental Response Pattern +85%
🔬 Research Context: Reflects exploratory model observations involving motility-related markers and laboratory signaling interpretation.
🧠 NEUROLOGICAL

Neurologic Model Observation

Focus on functional observation markers in preclinical neurological models and oligodendrocyte-related pathway signaling behavior.

Oligodendrocyte signaling ↑ Observed
Preclinical Markers ↑ Investigated
Experimental Timing Data 14-56 Days
Source: Investigative literature reports functional observation markers in preclinical neurologic settings.
👁️ OPHTHALMOLOGY

Corneal Model Evaluation

Framed as ocular surface laboratory model evaluation and investigational pathway signaling behavior.

Phase 2
Investigational Ophthalmic Reporting
✨ Study Setting: Ophthalmic literature may reference epithelial response observation without clinical benefit implications.
Status: Investigational pathway signaling behavior and research model reporting.
🔗 RESEARCH COMBINATIONS

Complementary Peptide Review

Comparative mechanism review across distinct research peptides may note overlapping interest in signaling behavior.

TB-500 Primary Actin-related signaling
Comparative Peptide Distinct pathway focus
Overlap Migration pathways
🔬 Comparative Note: Text remains framed as comparative mechanism review rather than outcome-oriented language.

Research Handling and Experimental Context

Available reporting should be interpreted through observed event frequency in limited datasets, handling considerations, and research context notes.

📊 COMMON REPORTED EVENTS
15%

Headache Signal (Reported Frequency)

MILD
10%

Upper Respiratory Event Signal

MILD
5%

Administration-Site Signal

MILD
⚠️ THEORETICAL CONCERNS

Theoretical Research Considerations

Available reporting on TB-500 includes limited investigational observations. For compliant implementation, event reporting should be treated as dataset-specific and non-conclusive.

• Dataset-specific reporting is not a safety characterization
• Preclinical discussion may reference signaling behavior
• Human safety characterization is not established
• Confined to laboratory model evaluation
📋 TOLERABILITY SUMMARY

Limited Dataset Summary

Serious Adverse Events 0 (Limited Dataset)
Dose-Limiting Toxicities 0 (Limited Dataset)
Study Discontinuation 0 (Limited Dataset)
💡 Observations come from limited investigational datasets
💡 Non-conclusive and context-specific reporting
🚫 HANDLING LIMITATIONS

Research-Use Protocol

Not Approved for General Use No Regulatory Approval for Consumption Limited Long-term Characterization Confined to Laboratory Evaluation Controlled Research Use Only Follow Laboratory Protocols
💡 Laboratory Handling Notes
  • Event reporting should be treated as dataset-specific and non-conclusive.
  • Long-term human safety characterization is not established.
  • Interpretation remains confined to laboratory model evaluation and document review.

Compound Information

TB-500 is commonly described as a synthetic thymosin beta-4 fragment research peptide studied for pathway signaling behavior connected to actin regulation and peptide movement dynamics. This technical section supports laboratory peptide signaling studies by summarizing sequence length, peptide class, storage conditions, and investigational context.

🔬 MOLECULAR PROFILE

What Is TB-500?

TB-500 is a synthetic thymosin beta-4 fragment research peptide studied for actin regulation and peptide movement dynamics in laboratory signaling studies.

Synthetic peptide fragment 43 amino acids
Type Synthetic Tβ4 Fragment
CAS Number 77591-33-4
Molecular Weight 4,963 Da
Amino Acids 43
Peptide Class Research Fragment
↗ Technical Reference
🧊 STORAGE REQUIREMENTS

Storage Expectations

Proper handling ensures molecule profile integrity and purity verification within controlled laboratory settings.

Protect from light Store desiccated
❄️
Lyophilized (powder)
-20°C ・ Long-term handling
🌡️
Reconstituted
2-8°C ・ Controlled conditions
⚠️
Avoid
Repeated freeze-thaw cycles
📋 RESEARCH STATUS

Where It Stands

This compound is presented as a research peptide within investigational documentation for pathway signaling studies.

Research Status Investigational
Approval Not for general use
Documentation Signaling studies
Use Context Laboratory research
Verification Purity verified
↗ Investigational Context

📚 Research Bibliography

Sources & References

All clinical data and research findings cited on this page are sourced from peer-
reviewed journals and official publications.

Expert Opinion on Biological Therapy

hymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

Goldstein AL, Hannappel E, Sosne G, Kleinman HK
2012 PMID: 22074294
Annals of the New York Academy of Sciences

A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

Ruff D, Crockford D, Girardi G, Zhang Y
2010 PMID: 20536472
Journal of the Neurological Sciences

A Dose Response Study of Thymosin β4 for the Treatment of Acute Stroke

Morris DC, Cui Y, Cheung WL, Lu M, Zhang L, Zhang ZG, Chopp M
2014 PMID: 25060418
Journal of Investigative Dermatology

Thymosin beta4 accelerates wound healing

Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK
1999 PMID: 10469335
International Journal of Molecular Sciences

Progress on the Function and Application of Thymosin β4

Xing Y, et al.
2021 DOI: 10.3390/ijms222413136
Nature

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D
2004 PMID: 15565145
Clinical Ophthalmology

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial

Sosne G, Ousler GW
2015 PMID: 26056426
Neuroscience

Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke

Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG
2010 PMID: 20627173
Journal of Neurosurgery

Treatment of traumatic brain injury with thymosin beta4 in rats

Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M
2010 PMID: 20486893
Nature

Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization

Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR
2007 PMID: 17108969

❓ Common Questions

Frequently Asked
Questions

TB-500 is a synthetic peptide sequence commonly discussed as a thymosin beta-4 fragment research
peptide. In research-supply positioning, it is described as a laboratory compound used for experimental
review of peptide signaling dynamics, actin-related pathway behavior, and model-based tissue-response
observation.

⚠️ Important Research Notice

This product is sold exclusively for in vitro research and educational purposes. It is not intended for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any medical condition or disease. All clinical trial data, research findings, and scientific information presented on this page are sourced from peer-reviewed academic publications. This content is provided for educational reference only and does not constitute medical advice, product claims, or treatment recommendations. By purchasing this product, the buyer confirms they are a qualified researcher and will use it strictly in accordance with all applicable federal, state, and local laws and regulations. GMR Peptides assumes no liability for any misuse of this product outside of a research context.

Website Exclusive

Welcome, researcher

Enter your email to unlock 20% off your first research supply order.

Please enter a valid email address.
No spam, unsubscribe anytime.
Your 20% discount is unlocked
PEP20

Shop Now With 20% Off
Apply as Affiliate